Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.63 |
| ▸ | CA2 | P00918 | 5/20 | 0.56 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.56 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 4/20 | 0.53 |
| ▸ | DHODH | Q02127 | 3/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14561993 | 0.86 | CACNA1G (0.67) | PTGS2CA2CACNA1GCACNA1HPTGS1 | |
| SCHEMBL3109266 | 0.85 | PTGS2 (0.52) | PTGS2CA2PTGS1EPHX2CA1 | |
| SCHEMBL3113061 | 0.83 | CA4 (0.53) | PTGS2CA2CACNA1GCACNA1HKMT2A | |
| SCHEMBL3098478 | 0.81 | CHRNA7 (0.51) | PTGS2CA2PTGS1EPHX2CA1 | |
| SCHEMBL14292740 | 0.81 | CA4 (0.54) | PTGS2CA2KMT2ACA1CA9 | |
| SCHEMBL3117397 | 0.80 | PTGS2 (0.58) | PTGS2CA2PTGS1KMT2ACA1 | |
| SCHEMBL3107422 | 0.79 | CA1 (0.56) | PTGS2CA2CACNA1GCACNA1HPTGS1 | |
| SCHEMBL3107727 | 0.78 | PTGS2 (0.50) | PTGS2CA2PTGS1EPHX2CA9 | |
| SCHEMBL3115632 | 0.78 | CA9 (0.53) | PTGS2CA2KMT2ACA1CA9 | |
| SCHEMBL3110187 | 0.75 | PTGS2 (0.53) | PTGS2CA2KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | CA2, CA7, CA9 | PTGS2 47/4885CA2 1/4885CACNA1G 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.